KZIA Kazia Therapeutics Limited
$8.17▲ +3.81%
Healthcare
Other
Volume 231.9K
Avg Volume (10D) 270.8K
Key Metrics & Fundamentals
Market Cap
$93.36M
P/E Ratio
–
Div Yield
0.00%
52W Range
4.86 - 17.40
% vs 50 MA
-22.65%
% vs 200 MA
-22.30%
RSI-14
41.7
MACD Histogram
+0.1300
Beta (1Y vs SPY)
2.46
Gross Rev
–
Gross Profit
–
EBITDA
–
COGS
–
Operating Exp
–
Operating Income
–
EBIT
–
Pretax Income
–
Net Income
–
Price & Volume History
Loading chart…
Recent News
Guggenheim Initiates Kazia Therapeutics at Buy With $35 Price Target
MT Newswires · Oct 21, 2026 7:28 AM ET
Leerink Partners Initiates Coverage on Kazia Therapeutics With Outperform, $30 Price Target
MT Newswires · Oct 20, 2026 7:19 AM ET
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
PR Newswire · Sep 22, 2026 7:30 AM ET
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
CNW Group · Sep 22, 2026 7:30 AM ET
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
PR Newswire · Sep 22, 2026 7:30 AM ET
Bank of New York Mellon Corporation (BNY) Lost A Depositary Mandate
Simply Wall St. · Sep 19, 2026 6:15 PM ET
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
CNW Group · Sep 9, 2026 7:30 AM ET
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
PR Newswire · Sep 9, 2026 7:30 AM ET
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
PR Newswire · Sep 9, 2026 7:30 AM ET
Kazia (KZIA) Raises Approximately $40M in Gross Proceeds and Expands Paxalisib. Is the Capital Base Stronger than the Clinical Evidence?
Insider Monkey · Sep 9, 2026 12:05 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.